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Background and Objectives. Breast-conserving surgery represents the standard of care for the treatment of small breast cancers.
However, there is a population of patients who cannot undergo the standard surgical procedures due to several reasons such as age,
performance status, or comorbidity. Our aim was to investigate the feasibility and safety of percutaneous US-guided laser ablation
for unresectable unifocal breast cancer (BC).Methods. Between December 2012 andMarch 2017, 12 consecutive patients underwent
percutaneous US-guided laser ablation as radical treatment of primary inoperable unifocal BC. Results. At median follow-up of
28.5 months (range 6-51), no residual disease or progression occurred; the overall success rate for complete tumor ablation was
therefore 100%. No significant operative side effects were observed, with only 2 (13.3%) experiencing slight to mild pain during
the procedure, and all patients complained of a mild dull aching pain in the first week after procedure. Conclusions. Laser ablation
promises to be a safe and feasible approach in those patients who are not eligible to the standard surgical approach. However, longer
follow-up results and larger studies are strongly needed.
1. Introduction
Breast cancer (BC) is the most frequently occurring cancer in
women (28.8% of all cancer diagnosis) and the second most
common in the world, with an estimated lifetime risk of 1/10
women [1].
Despite the steady increase of the number of BC
newly diagnosed worldwide, its mortality has shown a
slight decrease in western countries. This might be due to
widespread screening programs, resulting in an increased
diagnosis of small tumors, and itmight be secondary to better
therapeutic strategies [2, 3]. Over 40% of women with newly
diagnosed BC are aged 65 years or older, and the median age
at diagnosis is around 60 years [4].
Although breast-conserving surgery (BCS) represents the
treatment of choice for small BC [5], elderly women often
receive less than this standard therapy. In a large study, which
involved over 120,000 women, decreased surgical rates were
associated with higher age due to several reasons such as
performance status or comorbidity [4, 6, 7].
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Therefore, in the last decade, in parallel to the increasing
age of patients with a diagnosis of breast cancer, there has
been a progressive demand forminimally invasive treatments
specifically aimed at BC [8–10].These treatments are not sub-
stitutes for breast surgery, which is still the primary treatment
of choice, but they could represent a radical treatment for
the nonoperable group of patients or for those who refuse
surgery. The approaches available include cryoablation [11–
15], radiofrequency [16, 17], microwave ablation [18], focused
ultrasound (US) [19, 20], and laser ablation [21, 22].
The purpose of our single-center retrospective study is to
assess the feasibility of ultrasound guided percutaneous laser
ablation (LA), as the treatment of small unifocal breast cancer
in nonoperable elderly patients and in patients who refuse
surgery.
2. Methods
We achieved the Internal Review Board (IRB) approval for
this trial, performed in a large university referral hospital
for breast disease. Written informed consent of patients was
required for the inclusion in this study. All procedures were
in accordance with the ethical standards of the institutional
and/or national research committee and with the 1964
HelsinkiDeclaration and its later amendments or comparable
ethical standards.
The primary objectives of our study are to (i) describe the
results of laser ablation in nonoperable patients with unifocal
BC and (ii) assess the effectiveness and safety of LA to treat
BC.
The secondary objectives would be to (i) evaluate the
breast cosmesis, (ii) determine regional and distant breast
tumor recurrence rate up to 5 years, and (iii) determine the
overall survival rate among the period of the study.
2.1. Patient Selection and Period of Study. We retrospectively
reviewed 12 breast cancer patients who underwent percuta-
neous procedures in our Department of Breast Diagnostic
SenologyUnit of the Careggi Hospital, Italy, betweenDecem-
ber 2012 and March 2017. The multidisciplinary team of our
department carefully selected elderly patients (>75 years),
with inoperable breast cancer, due to comorbidities and/or to
high anesthetic risks, or who refuse surgery.
The inclusion criteria were as follows:
(1) unresectable unifocal BC due to comorbidity (e.g.,
severe cardiovascular or respiratory comorbidities,
age, performance status),
(2) tumor size ≤ 20 mm in the greatest diameter,
(3) the necessity of lesion being US visible at the time of
treatment,
(4) tumor located at least 1.0 cm from the chest wall as
well as the skin and nipple at USG,
(5) a biopsy proving invasive ductal unifocal, mucinous,
or tubular carcinoma.
The exclusion criteria were as follows:
(1) patients suitable for surgery or radiation approach,
(2) patients with multifocal or multicentric tumors,
(3) absence of written informed consent.
2.2. Procedure Planning. All patients underwent clinical and
radiological assessments prior to the laser ablation. Clinical
assessment included physical breast examination to exclude
skin or nipple involvement.
2.3. Breast Mammogram and Ultrasound. Radiological as-
sessment included a bilateral two-projection 2D-3D mam-
mography (MMG) (Selenia Dimensions, Hologic, Bed-
ford, USA) and ultrasonographic (US) examinations were
performed using a 10–13 MHz transducer and a US unit
(ESAOTE, MyLab 70 XVG, Genoa, Italy).
2.4. UltrasoundGuided Biopsy. All lesions were sampledwith
US-guided core-needle biopsy (CNB) using a 10 cm 14-gauge
cutting needle with a 22 mm throw (Precisa, HS Hospital
Service, Rome, Italy). A mean of 4 samples (range 3-5 sam-
ples) was taken in each case to evaluate the histological and
biological parameters of the tumor. Specimens underwent a
standard histological evaluation.
2.5. Laser Ablation Procedure. The procedure needed an
ultrasound interventional suite. Procedures were performed
by using a commercially available US system with an inte-
grated laser source with a 1064 nm wavelength (EchoLaser;
Elesta, Calenzano, Italy).
In each case, procedure needed the presence of an
anesthesiologist in the ultrasound interventional room and
available venous access. Generally, patients underwent local
anesthesia; we used conscious sedation only if indicated.
The operator inserts the 21G spinal needle in the most
suitable direction to reach the lesion following the shortest
possible path. Then the operator introduces and advances
a 300 𝜇m flat-tip laser fiber to the tip of the needle. The
introducer-needle was designed to expose the fiber tip of 5
mm. The procedure must provide a safe distance of 1.0 cm
from the skin and 1.0 cm from the chest wall. The operator
must progressively move the device LA (introducer-needle
and fiber) towards the target, choosing the best path to
correctly position the tip of the fiber. It is necessary to make
sure that the path of the applicator is as parallel as possible
to the chest wall. The tip of the device must always be in the
center of the lesion and its positionmust always be controlled
with two-plane ultrasound images (Figure 1).
According to previous experiences of other authors in
other applications of the thin needle laser methodology,
each treatment was performed with a fixed power protocol
(3W), modifying the lighting time according to the size of
the tumor. Depending on the size of the tumor at baseline,
the operator performs one or two consecutive illuminations
with a “pull-back” technique during the same treatment
session.The treatment ends when the gas, formed during the
ablation, covers the entire desired area or up to 1800 J for
illumination. Each ablation time varies from a minimum of
600 seconds (for tumor size up to 1.0 cm) to a maximum
of 1200 seconds (for tumor size between 1.0 and 2.0 cm), in
order to maintain the total energy applied between 1800 and
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Figure 1: The device LA (introducer-needle and fiber) must be
progressively inserted towards the target, choosing the best path to
correctly position the tip of the fiber. It is necessary to ensure that
the path of the applicator is as parallel as possible to the chest wall.
The tip of the device should always be inserted at the center of the
lesion and its position must always be controlled with two-plane
ultrasound images.
3600 J, respectively [23–26]. Patient vital signs monitoring
was continuous during all of the procedure.
In all cases, the laser fiber was active during the retraction
of the needle, in order to prevent a possible seeding of tumor
cells along the needle tract. Patient monitoring continued
up to 2–4 hours, in order to exclude unexpected acute
complications, and patient discharge occurred subsequently,
during the same day.
2.6. Follow-Up of Patients. Clinical follow-up began after
1 week, then at 3 months, and every 6 months until the
fifth year. Clinical examination assessed the skin and nipple
conditions and it evaluated the clinical size of the treated
lesion, if palpable. Radiological follow-up included a weekly
US examination from the 1st and 4th week after the ablation
procedure. Follow-up also included bilateral mammography
and ultrasound after 6 months from the laser procedure and
every 12 months thereafter up to 5 years.
The radiologist who performed the LA procedure was
the same that performed the ultrasound and mammographic
image evaluation. We have observed modifications of treated
site after the procedure, and we have considered as sugges-
tive of ablation/recurrence the radiologic aspects observed.
Complete ablation corresponded to awell-demarcated area of
coagulation zone at the previously ablated site on ultrasound.
Definition of recurrences were as follows:
(1) Local
(i) The previously ablated area had an ill-definedmargin,
and a soft tissue echogenicity within 10 mm of the
ablated margin was seen.
(ii) The previously ablated region increased in size.
(2) Distant
(i) New lesion was at >10 mm from the ablated margin.
Table 1: Data of patients and diagnostic findings prior to treatment.
Characteristic Value
Median age (range) 79.25 (75-92)
Postmenopausal, % (𝑛) 100 (12/12)
Right breast, % (𝑛) 41.7%, 5/12
Left breast, % (𝑛) 58.3%, 7/12
Median ultrasound tumor size (mm) (range) 12.72 (range 0.7-20)
Histology, % (𝑛)
(i) Ductal carcinoma 83.3% (10/12)
(ii) Mucinous carcinoma 8.3% (1/12)
(iii) Tubular carcinoma 8.3% (1/12)
2.7. Complications. Major complications were related to
admission to the hospital for therapy, an unplanned increase
in the level of care, prolonged hospitalization (more than
3 days), permanent adverse sequelae, or death. Any other
complication was considered minor.
We have recorded complications of treatment according
to the Society of Interventional Radiology (SIR) guidelines
[27, 28].
2.8. Survival. Overall survival was defined as the time from
the initial laser ablation session until death or the last patient
contact. The follow-up for this study ended in March 2017.
3. Results
3.1. Demographic Analysis of Study Population. Data of 12
patients with invasive breast cancers are summarized in
Table 1. Their mean age was 79.2 years (range 75-92). All
patients were postmenopausal.
They have completed preliminary diagnostic phase in a
mean of 11 days before the laser treatment (range 1-60), and
they underwent laser ablation in the US-dedicated room,
through local and conscious anesthesia. Mean US-based
ablated lesion size was 12.72 mm (range 0.7-20).
Five (41.7%, 5/12) tumors were located in the right breast
while seven (58.3%, 7/12) tumors were in the left breast.
The pathological diagnoses of the carcinomas were 10 ductal
infiltrating (83.3%, 10/12), 1 mucinous (8.3%, 1/12), and 1
tubular (8.3%, 1/12). Table 2 reported the clinical and US
assessment prior to ablation.
3.2. Laser Ablation Analysis. The fibers were placed into the
center of the lesion of each tumor, and LA was completed
according to a planned protocol in all sessions with a
technical success rate of 100 %. The overall treatment time
ranged from 20 to 35 minutes.
Response to the treatment was evaluated using US after 1
to 4 weeks, with US and mammogram at 6 months, and then
annually up to 5 years.
At the site of ablation, all lesions showed a well-
demarcated cystic lesion, visible at the 6-month US and
compatible with coagulative necrosis.The overall success rate
for complete tumor ablation (CTA) was 100% (Figures 2-3).
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Table 2: Patients characteristics.
Patient Number Reason for non-operability Age (Years) USG tumor size (Pre-biopsy) (mm)
01 Hypertension (HTN) and diabetes mellitus (DM) 80 15 mm
02 Congestive heart failure with DM 88 15 mm
03 CVS co-morbidity and HTN 83 10 mm
04 Ischemic heart disease 84 15 mm
05 DM with end stage renal disease 87 12 mm
06 Cardiomyopathy 86 10 mm
07 Patient refused operation 90 7 mm
08 CVS co-morbidity and pacemaker 85 15 mm
09 Patient refused operation 75 11 mm
10 Age factor with diabetes and hypertension 92 12 mm
11 Parkinson’s 90 20 mm
12 Congestive heart failure 88 15 mm
(a) (b)
Figure 2: Representative case of successful LA ablation in a patient with invasive ductal unifocal breast carcinoma of 18 mm of max diameter
in the upper outer quadrant of the right breast. (a) The US image before treatment shows the hypoechoic lesion with ill-defined margins and
the fine needle and the tip of the fiber in the outer third of the tumor mass. (b) The US image at the end of the treatment shows an evident
shadow cone due to the presence of gas bubbles that completely cover the ablated area.
At mammography, the necrotic lesion appeared as a typical
area of steatonecrosis (Figure 4).
Follow-up lasted a mean time of 28.5 months (range 6-
51). None of the patients demonstrated evidence of local or
distant recurrence during follow-up. No breast cancer related
deaths occurred in any of the patients.
3.3. Complications. During the procedure, 2 (16.6%, 2/12)
patients complained of mild pain and required conscious
sedation.The remaining patients well tolerated the procedure
with local anesthesia. However, all the patients experienced
a minimal aching sensation at the ablation site during the
first week after the procedure (SIR class A) [27, 28]. There
were no complications of skin burns in the posttreatment
clinical follow-up. The overall treatment time ranged from
20 to 35 minutes. Patients did not need hospitalization;
they underwent procedure and they discharged the same
day.
None of the patients sustained any systemic adverse
effects and there was no evidence of postablation hematoma,
infection, or skin burns.
4. Discussion
The main advantages of minimally percutaneous therapies
included the non-invasiveness, the good cosmesis, the lower
painfulness, the short recovery time, and the possibility
of a daycare procedure. These factors reduce the cost of
hospital stay and they potentially lower risks ofmorbidity and
mortality, in this group of elderly patients.
Our study showed that percutaneous laser ablation is
a feasible and effective option for selected unresectable BC
patients. Wemanaged to obtain complete ablation in patients
with small lesions (T1 lesions≤ 20mm).We excluded invasive
lobular carcinoma and ductal carcinoma in situ, due to the
unfavorable results with otherminimally invasive techniques,
as shown by previous reports [22].
In line with the above-mentioned studies, we chose US
to guide the treatment, since it was effective in showing the
real-time correct positioning of the needle at the center of the
lesion and the change in echogenicity during treatment. In
all cases, the increased echogenicity had an effect of partial
hiding of the treatment area (fog-effect). This is due to high
temperatures close to the fiber tip when it reaches over 100∘C
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(c) (d)
Figure 3: Another example of successful LA ablation in a patient with invasive ductal carcinoma of 15 mm of max diameter in the upper
outer quadrant of the right breast. (a) The US image before treatment shows the hypoechoic lesion with blurred margins. (b) The US image
shows the laser applicator (21G needle and fiber) which, with a course parallel to the chest wall, reaches the outer edge of the lesion. (c) Finally,
the lesion is no longer appreciable, and in the treated area, there is an echogenic line with an evident shadow cone. (d) The US image of the
ablated area in the first hours after treatment appears in the form of a heterogeneous predominantly hyperechoic zone (gas bubbles) with
blurred margins.
and the secondary formation of air bubbles [22]. The choice
of the amount of energy administered to ablate the treated
lesions accorded with previous reports [23–26].
The choice of lesions up to 20mm in the greatest diameter
is due to the waited association between the success rate
of laser ablation and tumor size. The fine needle approach
offered the maximum flexibility and it allowed a tailored
approach to the characteristics and location of the tumor.
Increased experience of the radiologist could lead to the
ablation of larger lesions. None of our patients demonstrated
a radiological disease progression.
A breast MRI would have been an ideal contrasted
baseline examination in addition to the mammogram and
ultrasound, since it represents one of the most sensitive
techniques to assess the real extention of the lesion [29,
30]. However, in our group of patients, considering the
age factor and associated comorbidities of renal failure and
pacemakers in situ, we could not perform an MRI as a
baseline examination to all patients. This can represent a
limitation of our study.
Other limitation is related to the type of evaluation
after treatment, depending only on the imaging, without
histological confirmation of the response to the treatment. A
future prospective study is going to need a longer follow-up
and an evaluation of efficacy, proved through a biopsy after
treatment.
Moreover, in other case reports about small lesions (up
to 15 mm), authors have reported response rates to ablative
technique through mammography and US [21].
Less than 15% of our patients showed complications as
mild pain during procedure,while all the patients complained
of a mild dull aching pain after procedure. Long-term
cosmetic result was also satisfactory. Among the limitations
of the study, there is the small number of patients, highly
selected in the group of elderly patients affected by unifocal
tumors who are nonsurgical candidates. However, through
our pilot study, we can state that laser ablation can be usefull
and feasible in the treatment of single small breast cancers
with complete necrosis of the lesion, good cosmetic outcome,
and cost effectiveness.
5. Conclusion
Laser ablation is a feasible, minimally invasive, and cost-
effective alternative for a subset of patients affected by small
lesions, who are not eligible to the standard surgical approach,
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Figure 4: Sequential mammograms showing the cystic oil formation by steatonecrosis over a period of 24 months. (a) Before LA (white
arrow) and (b) 24 month after a single laser treatment (white arrow).
as well as for patients who refuse surgery. However, further
larger prospective studies are strongly needed in order to
confirm our preliminary results.
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